nnpNeurology, Neuropsychiatry, PsychosomaticsНеврология, нейропсихиатрия, психосоматика2074-27112310-1342"IMA-Press", LLC10.14412/2074-2711-2025-4-26-32nnp-2657Research ArticleORIGINAL INVESTIGATIONSОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИThe role of noradrenaline in regulating the interaction between CD14+ monocytes and CD4+ T cells in multiple sclerosisРоль норадреналина в регуляции взаимодействия CD14+ моноцитов и CD4+ Т-клеток при рассеянном склерозеhttps://orcid.org/0009-0008-0113-6555НиколаеваД. В.NikolaevaD. V.

117997, Москва, ул. Островитянова, 1

1, Ostrovityanova St., Build. 10, Moscow 117997

https://orcid.org/0000-0002-1266-5304ЖетишевР. Р.ZhetishevR. R.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10

1, Ostrovityanova St., Build. 10, Moscow 117997; 1, Ostrovityanova St., Moscow 117997

https://orcid.org/0000-0002-1380-8442ЛопатинаА. В.LopatinaA. V.

117997, Москва, ул. Островитянова, 1

https://orcid.org/0000-0003-1086-9052СвиридоваА. А.SviridovaA. A.

117997, Москва, ул. Островитянова, 1

https://orcid.org/0009-0006-0807-2529ЕсиповаД. Д.EsipovaD. D.

117997, Москва, ул. Островитянова, 1; 121374, Москва, Можайское шоссе, 14

1, Ostrovityanova St., Build. 10, Moscow 117997; 14, Mozhaiskoe Sh., Moscow 121374

https://orcid.org/0000-0001-7000-5729МуругинаН. Е.MuruginaN. E.

117997, Москва, ул. Островитянова, 1; 121374, Москва, Можайское шоссе, 14

1, Ostrovityanova St., Build. 10, Moscow 117997; 14, Mozhaiskoe Sh., Moscow 121374

https://orcid.org/0000-0002-1011-2554МуругинВ. В.MuruginV. V.

117997, Москва, ул. Островитянова, 1; 121374, Москва, Можайское шоссе, 14

1, Ostrovityanova St., Build. 10, Moscow 117997; 14, Mozhaiskoe Sh., Moscow 121374

https://orcid.org/0000-0002-2975-4151БойкоА. Н.BoykoA. N.

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10

1, Ostrovityanova St., Build. 10, Moscow 117997; 1, Ostrovityanova St., Moscow 117997

https://orcid.org/0000-0001-6880-3668МельниковМ. В.MelnikovM. V.

Михаил Валерьевич Мельников

117997, Москва, ул. Островитянова, 1; 117997, Москва, ул. Островитянова, 1, стр. 10; 121374, Москва, Можайское шоссе, 14

1, Ostrovityanova St., Build. 10, Moscow 117997; 1, Ostrovityanova St., Moscow 117997; 14, Mozhaiskoe Sh., Moscow 121374

medikms@yandex.ruФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА РоссииРоссияFederal Center for Brain and Neurotechnologies, FMBA of RussiaRussian FederationФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава РоссииРоссияFederal Center for Brain and Neurotechnologies, FMBA of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaRussian FederationФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России; ФГБУ Государственный научный центр «Институт иммунологии» ФМБА РоссииРоссияFederal Center for Brain and Neurotechnologies, FMBA of Russia; National Research Center Institute of Immunology, FMBA of RussiaRussian FederationФГБУ «Федеральный центр мозга и нейротехнологий» ФМБА России; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России; ФГБУ Государственный научный центр «Институт иммунологии» ФМБА РоссииРоссияFederal Center for Brain and Neurotechnologies, FMBA of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; National Research Center Institute of Immunology, FMBA of RussiaRussian Federation2025230820251742632Copyright © Nikolaeva D.V., Zhetishev R.R., Lopatina A.V., Sviridova A.A., Esipova D.D., Murugina N.E., Murugin V.V., Boyko A.N., Melnikov M.V., 20252025Николаева Д.В., Жетишев Р.Р., Лопатина А.В., Свиридова А.А., Есипова Д.Д., Муругина Н.Е., Муругин В.В., Бойко А.Н., Мельников М.В.Nikolaeva D.V., Zhetishev R.R., Lopatina A.V., Sviridova A.A., Esipova D.D., Murugina N.E., Murugin V.V., Boyko A.N., Melnikov M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://nnp.ima-press.net/nnp/article/view/2657

Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects young people. It has been established that CD14+ monocytes and T-helpers (CD4+ T cells) play an important role in both the development and maintenance of autoimmune neuroinflammation in MS. Noradrenaline is one of the key neurotransmitters of the CNS, which, along with regulating neuropsychological functions, also participates in the modulation of cells of the innate and adaptive immune response.

Objective

Objective: to investigate the effect of noradrenaline on CD14+ monocyte-induced activation of CD4+ T cells in patients with relapsing-remitting MS.

Materials and methods

Materials and methods. A comprehensive clinical and immunological examination was conducted on 12 patients with relapsing-remitting MS and 12 healthy donors. The effect of noradrenaline on the production of interleukin 6 (IL6) and IL1 β by CD14+ monocytes, which are necessary for the differentiation of Th17 cells, as well as on the activation of the PKA–CREB signalling pathway in CD14+ monocytes, was assessed. In addition, the effect of noradrenaline on the ability of CD14+ monocytes to induce the production of IL17 and interferon γ by autologous CD4+ T cells was evaluated.

Results

Results. Noradrenaline suppressed cytokine production by CD14+ monocytes in both groups, as well as activation of the PKA–CREB signalling pathway in the group of healthy donors. Noradrenaline also suppressed the ability of CD14+ monocytes to induce IL17 production by autologous CD4+ T cells in both groups.

Conclusion

Conclusion. Preliminary data indicate that noradrenaline has an anti-inflammatory effect in MS, which may be mediated by its influence on the function of CD14+ monocytes.

Рассеянный склероз (РС) – аутоиммунное демиелинизирующее и нейродегенеративное заболевание центральной нервной системы (ЦНС), поражающее лиц молодого возраста. Установлено, что CD14+ моноциты и Т-хелперы (CD4+ Т-клетки) играют важную роль как в развитии, так и в поддержании аутоиммунного нейровоспаления при РС. Норадреналин – один из ключевых нейротрансмиттеров ЦНС, который наряду с регуляцией нейропсихологических функций также участвует в модуляции клеток врожденного и адаптивного иммунного ответа.

Цель исследования – изучить влияние норадреналина на индуцируемую CD14+ моноцитами активацию CD4+ T-клеток у больных ремиттирующим РС.

Материал и методы

Материал и методы. Проведено комплексное клиническое и иммунологическое обследование 12 больных ремиттирующим РС и 12 здоровых доноров. Оценивали влияние норадреналина на продукцию CD14+ моноцитами интерлейкина 6 (ИЛ6) и ИЛ1β, которые необходимы для дифференцирования Th17-клеток, а также на активацию в CD14+ моноцитах сигнального пути PKA–CREB. Кроме того, оценивали влияние норадреналина на способность CD14+ моноцитов индуцировать продукцию ИЛ17 и интерферона γ аутологичными CD4+ Т-клетками.

Результаты

Результаты. Норадреналин подавлял продукцию цитокинов CD14+ моноцитами в обеих группах, а также активацию сигнального пути PKA–CREB в группе здоровых доноров. Также норадреналин подавлял способность CD14+ моноцитов индуцировать продукцию ИЛ17 аутологичными CD4+ Т-клетками в обеих группах.

Заключение

Заключение. Полученные предварительные данные указывают на противовоспалительный эффект норадреналина при РС, который может быть опосредован его влиянием на функции CD14+ моноцитов.

норадреналинCD14+ моноцитыCD4+ Т-клеткицитокинырассеянный склерозnoradrenalineCD14+ monocytesCD4+ T cellscytokinesmultiple sclerosisИсследование выполнено при финансовой поддержке Российского научного фонда в рамках научного проекта № 2275-10119. Исследование не имело спонсорской поддержкиThe study was conducted with financial support from the Russian Science Foundation as part of scientific project No. 22-75-10119. The investigation has not been sponsoredReferencesWalton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-21. doi: 10.1177/1352458520970841Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-21. doi: 10.1177/1352458520970841Nally FK, De Santi C, McCoy CE. Nanomodulation of Macrophages in Multiple Sclerosis. Cells. 2019 Jun 5;8(6):543. doi: 10.3390/cells8060543Nally FK, De Santi C, McCoy CE. Nanomodulation of Macrophages in Multiple Sclerosis. Cells. 2019 Jun 5;8(6):543. doi: 10.3390/cells8060543Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009 May;10(5):514-23. doi: 10.1038/ni.1716Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol. 2009 May;10(5):514-23. doi: 10.1038/ni.1716Prineas JW, Parratt JDE. Multiple Sclerosis: Microglia, Monocytes, and MacrophageMediated Demyelination. J Neuropathol Exp Neurol. 2021 Oct 26;80(10):975-96. doi: 10.1093/jnen/nlab083Prineas JW, Parratt JDE. Multiple Sclerosis: Microglia, Monocytes, and MacrophageMediated Demyelination. J Neuropathol Exp Neurol. 2021 Oct 26;80(10):975-96. doi: 10.1093/jnen/nlab083Correale J, Halfon MJ, Jack D, et al. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021 Nov;56:103264. doi: 10.1016/j.msard.2021.103264Correale J, Halfon MJ, Jack D, et al. Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021 Nov;56:103264. doi: 10.1016/j.msard.2021.103264Melnikov M, Rogovskii V, Sviridova A, et al. The Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis. Int J Mol Sci. 2022 Jan 8;23(2):668. doi: 10.3390/ijms23020668Melnikov M, Rogovskii V, Sviridova A, et al. The Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis. Int J Mol Sci. 2022 Jan 8;23(2):668. doi: 10.3390/ijms23020668Pilipovic I, Stojic-Vukanic Z, Leposavic G. Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis. Pharmacol Ther. 2023 Mar;243:108358. doi: 10.1016/j.pharmthera.2023.108358Pilipovic I, Stojic-Vukanic Z, Leposavic G. Adrenoceptors as potential target for add-on immunomodulatory therapy in multiple sclerosis. Pharmacol Ther. 2023 Mar;243:108358. doi: 10.1016/j.pharmthera.2023.108358Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018 Feb;17(2):162-73. doi: 10.1016/S1474-4422(17)30470-2Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444-52. doi: 10.1212/wnl.33.11.1444Han TH, Jin P, Ren J, et al. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferongamma. J Immunother. 2009 May;32(4):399-407. doi: 10.1097/CJI.0b013e31819e1773Han TH, Jin P, Ren J, et al. Evaluation of 3 clinical dendritic cell maturation protocols containing lipopolysaccharide and interferongamma. J Immunother. 2009 May;32(4):399-407. doi: 10.1097/CJI.0b013e31819e1773Spiljar M, Steinbach K, Rigo D, et al. Cold exposure protects from neuroinflammation through immunologic reprogramming. Cell Metab. 2021 Nov 2;33(11):2231-46.e8. doi: 10.1016/j.cmet.2021.10.002Spiljar M, Steinbach K, Rigo D, et al. Cold exposure protects from neuroinflammation through immunologic reprogramming. Cell Metab. 2021 Nov 2;33(11):2231-46.e8. doi: 10.1016/j.cmet.2021.10.002Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2008 Mar;131(Pt 3):785-99. doi: 10.1093/brain/awm295Ifergan I, Kebir H, Bernard M, et al. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain. 2008 Mar;131(Pt 3):785-99. doi: 10.1093/brain/awm295Jiao L, Guo S. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol. 2022 Oct 27;13:966766. doi: 10.3389/fimmu.2022.966766Jiao L, Guo S. Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases. Front Immunol. 2022 Oct 27;13:966766. doi: 10.3389/fimmu.2022.966766Mendiola AS, Cardona AE. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018 May;125(5):781-95. doi: 10.1007/s00702-017-1732-9Mendiola AS, Cardona AE. The IL-1β phenomena in neuroinflammatory diseases. J Neural Transm (Vienna). 2018 May;125(5):781-95. doi: 10.1007/s00702-017-1732-9Ng TM, Toews ML. Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol. 2016 Oct 26;8(10):584-9. doi: 10.4330/wjc.v8.i10.584Ng TM, Toews ML. Impaired norepinephrine regulation of monocyte inflammatory cytokine balance in heart failure. World J Cardiol. 2016 Oct 26;8(10):584-9. doi: 10.4330/wjc.v8.i10.584Dimitrov S, Hulteng E, Hong S. Inflammation and exercise: Inhibition of monocytic intracellular TNF production by acute exercise via β2-adrenergic activation. Brain Behav Immun. 2017 Mar;61:60-8. doi: 10.1016/j.bbi.2016.12.017Dimitrov S, Hulteng E, Hong S. Inflammation and exercise: Inhibition of monocytic intracellular TNF production by acute exercise via β2-adrenergic activation. Brain Behav Immun. 2017 Mar;61:60-8. doi: 10.1016/j.bbi.2016.12.017De Keyser J, Laureys G, Demol F, et al. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int. 2010 Nov;57(4):446-50. doi: 10.1016/j.neuint.2010.02.012De Keyser J, Laureys G, Demol F, et al. Astrocytes as potential targets to suppress inflammatory demyelinating lesions in multiple sclerosis. Neurochem Int. 2010 Nov;57(4):446-50. doi: 10.1016/j.neuint.2010.02.012Boyko A, Melnikov M, Zhetishev R, Pashenkov M. The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis. Neuroimmunomodulation. 2016;23(4):217-23. doi: 10.1159/000449167. Epub 2016 Oct 7.Boyko A, Melnikov M, Zhetishev R, Pashenkov M. The Role of Biogenic Amines in the Regulation of Interaction between the Immune and Nervous Systems in Multiple Sclerosis. Neuroimmunomodulation. 2016;23(4):217-23. doi: 10.1159/000449167. Epub 2016 Oct 7.Rajda C, Bencsik K, Vecsei LL, Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol. 2002 Mar;124(1-2):93-100. doi: 10.1016/s0165-5728(02)00002-4Rajda C, Bencsik K, Vecsei LL, Bergquist J. Catecholamine levels in peripheral blood lymphocytes from multiple sclerosis patients. J Neuroimmunol. 2002 Mar;124(1-2):93-100. doi: 10.1016/s0165-5728(02)00002-4Zaffaroni M, Marino F, Bombelli R, et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol. 2008 Dec;214(2):315-21. doi: 10.1016/j.exp-neurol.2008.08.015. Epub 2008 Sep 12.Zaffaroni M, Marino F, Bombelli R, et al. Therapy with interferon-beta modulates endogenous catecholamines in lymphocytes of patients with multiple sclerosis. Exp Neurol. 2008 Dec;214(2):315-21. doi: 10.1016/j.exp-neurol.2008.08.015. Epub 2008 Sep 12.

The authors declare that there are no conflicts of interest present.